NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

TerminatedN/A

Sponsor: AstraZeneca

Conditions: Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD)

Countries: Russia

This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Adults (≥18 years) with a confirmed diagnosis of AQP4-IgG positive NMOSD following the 2015 IPND criteria;
2. Provision of signed and dated written informed consent.

Exclusion Criteria:

1.Participants currently enrolled in clinical studies for the treatment of NMOSD.

Locations (1)

Novosibirsk, Russia